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Receptor-Binding, Biodistribution, and Metabolism
Studies of 64Cu-DOTA-Cetuximab, a PET-Imaging
Agent for Epidermal Growth-Factor 
Receptor-Positive Tumors
Wen Ping Li, Laura A. Meyer, David A. Capretto, Christopher D. Sherman, 
and Carolyn J. Anderson
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO
ABSTRACT
The epidermal growth-factor receptor (EGFR) and its ligands have been recognized as critical factors in the
pathophysiology of tumorigenesis. Overexpression of the EGFR plays a significant role in the tumor pro-
gression of a wide variety of solid human cancers. Therefore, the EGFR represents an attractive target for
the design of novel diagnostic and therapeutic agents for cancer. Cetuximab (C225, Erbitux®) was the first
monoclonal antibody targeted against the ligand-binding site of EGFR approved by the Food and Drug Ad-
ministration for the treatment of patients with EGFR-expressing, metastatic colorectal carcinoma, although
clinical trials showed variability in the response to this treatment. The aim of this study involved using ce-
tuximab to design a positron emission tomography (PET) agent to image the overexpression of EGFR in tu-
mors. Cetuximab was conjugated with the chelator, DOTA, for radiolabeling with the positron-emitter, 64Cu
(T1/2  12.7 hours). 64Cu-DOTA-cetuximab showed high binding affinity to EGFR-positive A431 cells (KD of
0.28 nM). Both biodistribution and microPET imaging studies with 64Cu-DOTA-cetuximab demonstrated
greater uptake at 24 hours postinjection in EGFR-positive A431 tumors (18.49%  6.50% injected dose per
gram [ID/g]), compared to EGFR-negative MDA-MB-435 tumors (2.60%  0.35% ID/g). A431 tumor up-
take at 24 hours was blocked with unlabeled cetuximab (10.69%  2.72% ID/g), suggesting that the tumor
uptake was receptor mediated. Metabolism experiments in vivo showed that 64Cu-DOTA-cetuximab was rel-
atively stable in the blood of tumor-bearing mice; however, there was significant metabolism in the liver and
tumors. 64Cu-DOTA-cetuximab is a potential agent for imaging EGFR-positive tumors in humans.
Key words: epidermal growth-factor receptor, PET imaging, copper-64, monoclonal antibody
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cells. The epidermal growth factor (EGF) family
of membrane receptors is one of the most rele-
vant targets in this class. Epidermal growth-fac-
tor receptor (EGFR) is associated with oncogenic
transformation, and the dysregulation of EGFR
is associated with all of the key features of can-
cer, such as autonomous cell growth, invasion,
angiogenic potential, and the development of dis-
tant metastases.1 An increased expression of
EGFR is the hallmark of many human tumors,
such as breast cancer, squamous-cell carcinoma
INTRODUCTION
Membrane receptors of the tyrosine kinase fam-
ily are the best-characterized targets in cancer
of the head and neck, and prostate cancer. Acti-
vation of EGFR contributes to several other es-
sential tumorigenic mechanisms, including tumor
survival, invasion, angiogenesis, and metastatic
spread. In many tumors, EGFR expression may
act as a prognostic indicator, predicting poor sur-
vival and/or more advanced disease stage.2
Of several therapeutic approaches to target
EGFR, monoclonal antibodies (mAbs), which
block the binding of EGF to the extracellular li-
gand-binding domain of the receptor and small ty-
rosine kinase inhibitors, are the furthest along in
clinical development. In addition, mAbs inhibiting
EGFR were the first approach used in clinical stud-
ies to target the aberrant signaling of EGFR in ma-
lignant cells.1 As knowledge concerning the mo-
lecular nature of antigens associated with tumors
increased, antibodies that bind with high affinity
and specificity to cancer cells were developed. Ce-
tuximab (C225, Erbitux®) was the first mAb tar-
geted against the ligand-binding site of EGFR ap-
proved by the Food and Drug Administration for
the treatment of patients with EGFR-expressing,
metastatic colorectal carcinoma, although clinical
trials have revealed significant variability in the re-
sponse to this agent.3–5 Cetuximab binds competi-
tively to the extracellular domain of EGFR with an
affinity comparable to the natural ligand (KD  1.0
nM), inhibiting the binding of the activating ligand
to the receptor.6,7 Consequently, cetuximab bind-
ing inhibits the autophosphorylation of EGFR and
induces its internalization and degradation. The
effective use of this new therapeutic agent that tar-
gets EGFR will depend on the ability of physicians
to detect and characterize EGFR-expression in le-
sions before and after the initiation of treatments.
A radiopharmaceutical for noninvasively measur-
ing tumor EGFR overexpression in vivo would pro-
vide important information on the expression lev-
els of EGFR-targeting agents and potentially aid in
the optimization of cancer treatment plans.
The use of radiolabeled anti-EGFR antibodies
for EGFR-expressing cancer diagnosis has be-
come the subject of intense investigation as 
more mAbs with relevant, well-characterized
specificities become available. The 111In-labeled
anti-EGFR antibody, 425, successfully detected
malignant gliomas, and the 99mTc-labeled anti-
EGFR humanized antibody, hR3, is under clini-
cal evaluation.8,9 Cetuximab attached to the ra-
diometal chelator, diethylenetriaminepentaacetic
acid (DTPA), and labeled with 111In, was shown
to localize specifically in tumors that overexpress
EGFR.10,11 However, a considerable amount of
radioactivity in the liver was observed as a result
of nonspecific uptake, thereby limiting the clini-
cal usefulness of this agent for cancer imaging.
An improved cetuximab conjugate (DTPA-PEG-
cetuximab) was reported to overcome this prob-
lem, as tumor imaging of 111In-DTPA-PEG-
cetuximab in nude mice showed significant re-
duction of radioactivity in the liver using a
gamma camera.11 Although cetuximab Fab and
F(ab)2 fragments have been investigated, they
have reduced binding affinity (5-fold weaker) and
showed less inhibition of tumor growth than the
intact antibody.7 A smaller molecular weight “af-
fibody,” (Z(EGFR:955)),2 that binds to EGFR,
was labeled with 125I, demonstrating that this
technology holds promise for improving both tar-
geting and nontarget organ clearance, compared
to intact antibodies.12
The aim of this study involved using cetuximab
to design a positron emission tomography (PET)
imaging agent to image the overexpression of
EGFR in tumors. PET has an advantage in terms
of its greater sensitivity and higher resolution at
all depths than a gamma camera or single-pho-
ton emission tomography (SPECT). Copper-64
(half-life, 12.7 hours; 17.4%  [0.656 MeV];
39%  [0.573 MeV]) is an attractive positron-
emitting radionuclide for both PET imaging 
and radiotherapy and has a compatible half-life
with the slow blood clearance of an antibody. 
Cai et al. recently reported the evaluation of 
64Cu-DOTA-cetuximab in several tumor-bearing
mouse models.13 In the present study, we also re-
port on the development of 64Cu-DOTA-cetux-
imab for the small-animal imaging of EGFR ex-
pression. Additionally, we report in this paper on
the receptor binding of this radiopharmaceutical




butyl acetate)-10-acetic acid mono(N-hydroxy-
succinimide ester) (DOTA-mono-NHS-tris(tBu)
ester) was purchased from Macrocyclics (Dallas,
TX). Centricon 100 concentrators were pur-
chased from Amicon Inc. (Beverly, MA). Bio-
Spin 6 chromatography columns were from Bio-
Rad Laboratories (Hercules, CA). All chemicals
used were purchased from Sigma-Aldrich Chem-
ical Co. (St Louis, WI). All solutions were made
by using distilled deionized water (Milli-Q, Mil-
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lipore, Bedford, MA; 18 M resistivity). mAb
cetuximab (C225) was kindly provided by Im-
Clone Systems, Inc. (New York, NY). Eight (8)
to 10-week-old female athymic nude mice were
purchased from Charles River (Wilmington,
MA). A Branson Sonifier (Branson, Danbury,
CT) cell disrupter, a Tekmar (Tekmar, Malon,
OH) tissue homogenizer, and a Sorvall (Thomas
Scientific, Waltham, MA) RC2-B centrifuge
were used in the cell binding and animal metab-
olism experiments. Size-exclusion high-perfor-
mance liquid chromatography (HPLC), used in the
conjugation and purification of radiolabeled con-
jugate, and in metabolite analyses, was accom-
plished on a Superose 12 HR 10/300 column
(Amersham Biosciences, Uppsala, Sweden) with
a Waters (Milford, MA) 2487 dual  absorbance
detector and an Ortec Model 661 (EG&G Instru-
ments, Oak Ridge, TN) radioactive detector. The
mobile phase was 20 mM HEPES and 150 mM
NaCl [pH 7.3] eluted at a flow rate of 0.5 mL/min.
Millenium 32 software (Waters) was used to
quantify chromatograms by integration. A Beck-
man 8000 (Beckman, Fullerton, CA) automated
well-typed gamma counter was used to count
size-exclusion HPLC fractions of metabolite and
animal biodistribution samples. Levels of ra-
dioactivity greater than 0.05 MBq were assayed
in a Capintec dose calibrator (model-15R; Cap-
intec, Ramsey, NJ). Multiscreen 96-well mi-
crotiter plates for receptor-binding assays were
counted on a 1450 Microbeta Trilux Liquid Scin-
tillation and Luminescence Counter (PerkinElmer
Life Sciences, Downers Grove, IL). Copper-64 was
produced, as previously reported, on a biomedical
CS-15 cyclotron at the Washington University
School of Medicine (St. Louis, MO).14
Conjugation of DOTA to Cetuximab and
Radiolabeling with 64Cu
DOTA was conjugated to cetuximab in 0.1 M of
Na2HPO4 (pH 7.5), using an adaptation of the
method described by Rogers et al.15 Cetuximab (2
mg/mL) was washed with 0.1 M of Na2HPO4 (pH
7.5), using a Centricon 100 and then concentrated
prior to conjugation with DOTA-mono-NHS-
tris(tBu) ester. The volume of concentrated cetux-
imab was measured by pipetting and transferred
into an acid-washed microcentrifuge tube. DOTA-
mono-NHS-tris(tBu) ester was dissolved in 0.1 M
of Na2HPO4 (pH 7.4) and the pH was adjusted to
7.4 by adding 0.1 M of NaOH. An aliquot of this
solution was added to the concentrated cetuximab
in a 90:1 molar ratio (DOTA-mono-NHS-
tris(tBu)ester: cetuximab), followed by incubation
at 4°C overnight with end-over-end rotation. The
conjugate was then transferred to a Centricon 100,
diluted to 2.0 mL with 0.1 M of ammonium cit-
rate (pH 5.5), and centrifuged. This procedure was
repeated four times to remove small-molecule re-
actants, and the conjugate was collected from the
membrane. Purity and concentration of the result-
ing DOTA-cetuximab conjugate were determined
by size-exclusion HPLC and stored at 4 °C until
needed. Titration of DOTA-cetuximab with
[natCu]copper acetate spiked with 64Cu revealed
that the ratio of DOTA:cetuximab achieved by this
procedure was 5.5.16
DOTA-cetuximab labeling with 64Cu was car-
ried out by adding DOTA-cetuximab to 64CuCl2
in 0.1 M of ammonium citrate buffer [pH 5.5],
followed by incubation for 1 hour at 40°C. The
radiochemical purity of the resulting 64Cu-
DOTA-cetuximab was determined by size-exclu-
sion HPLC, and purification was performed by
using Bio-spin 6 or size-exclusion HPLC on a
Superose 12 HR 10/300 column, if necessary.
The specific activity ranged from 370 to 1110
MBq 64Cu per milligram of cetuximab.
Cell Lines and Tumor Xenograft 
Mouse Models
Human vulvar squamous carcinoma A431 cells
(high concentration of EGFR) were purchased
from the American Type Culture Collection
(ATCC; Manassas, VA) and maintained in Dul-
becco’s modified Eagle’s medium (DMEM) con-
taining 10% fetal bovine serum (FBS). Human
breast adenocarcinoma MDA-MB-435 cells (low
concentration of EGFR) were obtained from
Janet E. Price, PhD (MD Anderson Cancer Cen-
ter, Houston, TX)17 and grown in DMEM sup-
plemented with 10% FBS and antibiotics at 37°C
and 5% CO2. A431 cells have a high expression
of EGFR, whereas MDA-MB-435 cells express
low levels.10 Female nu/nu mice (8–10 weeks of
age) were injected subcutaneously with 5  106
A431 cells in the neck. Tumors reached appro-
priate size (0.3–0.5 g) on day 12, and all animal
studies were performed at 12 days post-tumor im-
plantation. The MDA-MB-435 human breast can-
cer model was established by injecting 4  105
cells/100 L in the right mammary fat pad of
8–10-week-old female nu/nu mice, and the ani-
mal studies were carried out at 2 weeks post-tu-
mor implantation.
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In Vitro Binding Affinity
The receptor-binding properties of 64Cu-DOTA-
cetuximab were evaluated in direct radioligand
competitive and saturation binding assays, using
A431 and MDA-MB-435 cell lines.10,18 Cell
membranes were prepared by following the
method described previously.19 Briefly, cells were
grown as a monolayer in 75 cm2 tissue culture
flasks (Falcon [BO Biosciences, San Jose, CA] or
Costar) to about 90% confluence. The cells were
gently washed with 3 mL of ice-cold 20 mM Tris-
HCl (pH 7.4) before the addition of 5 mL of cold,
freshly prepared homogenizing buffer (50 mM of
Tris-HCl, pH 7.4, 5.0 mM of MgCl2, 0.5 g/mL
of aprotinin, 200 g/mL of bacitracin, 1.0 mM
of ethylene glycol-bis[-aminoethyl ether], 10
g/mL of leupeptin, and 10 g/mL of pepstatin
A). Cells were then scraped from the walls of
flasks, homogenized with a Branson Sonifier cell
disrupter, and centrifuged on a Sorvall centrifuge
at 13,000 rpm at 4°C for 20 minutes. The pellets
were resuspended in homogenized buffer at 800
g/mL and stored at 80°C, if not used immedi-
ately. Both competitive and saturation binding as-
says were performed in 96-well microtiter plates,
using the Millipore MultiScreen System (Bedford,
MA). For the competitive binding assay, 40 g of
the membrane protein was incubated with 0.05 nM
of 64Cu-DOTA-cetuximab at room temperature
for 2 hours in a total volume of 250 L of bind-
ing buffer (0.1% bovine serum albumin [BSA] in
phosphate-buffered saline [PBS]) in the presence
or absence of 0.1–60 nM of unlabeled cetuximab.
After the incubation, the reaction buffer was re-
moved by using a vacuum drain and the cells were
washed two times with binding buffer. The plates
were counted on the microbeta counter after load-
ing 25 L of scintillation cocktail into each well.
The radioactivity bound to cells was plotted ver-
sus the increasing concentration of cetuximab to
determine the best-fit IC50 values by using Prism
software (v. 4.0; GraphPad, San Diego, CA). For
saturation binding experiments, 64Cu-DOTA-ce-
tuximab (0.05–32 nM) was incubated with 40 g
of A431 membrane protein for 2 hours at room
temperature, followed by the same procedure for
competitive binding, as described above. Nonspe-
cific binding was determined by conducting the
assay in the presence of an excess (200 nM) un-
labeled cetuximab. Specific binding was obtained
by the subtraction of nonspecific binding from to-
tal binding. The dissociation constant (KD) and re-
ceptor density (Bmax) were estimated from the
nonlinear fitting of the specific binding versus the
concentration of 64Cu-DOTA-cetuximab, using
Prism software. For statistical considerations, two
separate experiments for both competitive and sat-
uration binding assays were performed in tripli-
cate.
In Vivo Biodistribution and Micro-PET
Imaging Studies
Animal studies were conducted in accordance
with the highest standards of care, as outlined 
in the National Institutes of Health’s (NIH;
Bethesda, MD) Guide for Care and Use of Lab-
oratory Animals and the policy and procedures
for animal research at the Washington University
School of Medicine. The biodistribution and up-
take of 64Cu-DOTA-cetuximab were determined
in the A431 and MDA-MB-435 tumor-bearing
nude mice. Following injection of the mice with
aliquots of 64Cu-DOTA-cetuximab (100 L, 0.6
MBq, 1.2 g) through the tail vein, blood, or-
gans, and tumors were removed from animals eu-
thanized by cervical dislocation at 4, 24, and 48
hours postinjection (n  5 for each group). The
5 mice that were sacrificed at 48 hours postin-
jection were housed in individual metabolism
cages for the collection of urine and feces at 4,
24, and 48 hours for the determination of the per-
cent injected dose (%ID) excreted. For blocking
studies, an excess of unlabeled cetuximab (1 mg)
was injected into each mouse 20 hours before the
radiolabeled mAb solution. The radioactivity of
tissue samples was measured in a gamma counter.
The percent injected dose per gram (% ID/g) and
percent injected dose per organ (% ID/organ)
were calculated by comparison with standards
representing the injected dose per animal.
To delineate the uptake of 64Cu-DOTA-cetux-
imab in A431 tumors, a group of 6 A431 tumor-
bearing mice were anesthetized by the inhalation
of 2% isofluorane and administrated with 64Cu-
DOTA-cetuximab. Three (3) mice were injected
with an excess of unlabeled cetuximab (1 mg in
100 L PBS per mouse) 20 hours prior to the ad-
ministration of the imaging dose (5.6 MBq, 6 g).
Two (2) mice (control vs. block) were scanned
for 10–30 minutes side by side at 4, 20, 27, and
46 hours after the administration of 64Cu-DOTA-
cetuximab on a micro-PET Focus (model 120 or
220; Concorde Microsystems, Knoxville, TN). In
addition, the EGFR-mediated tumor uptake was
also evaluated by the comparison of A431 tumors
with MDA-MB-435 tumors by micro-PET. Four
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(4) mice (2 mice for each tumor model) were in-
jected with 64Cu-DOTA-cetuximab (5.6 MBq, 6
g), and two groups of 2 mice (A431 vs. MDA-
MB-435 tumor mice) were imaged following the
same protocol as described above. In a separate
experiment, 4 mice bearing both EGFR-positive
A431 and EGFR-negative MDA-MB-435 tumors
on their contralateral mammary fat pads were in-
jected with 64Cu-DOTA-cetuximab (7.8 MBq, 20
g) and scanned at 4 and 24 hours postinjection.
High-resolution, coregistration micro-CT imag-
ing was performed to monitor tumor volume and
morphology at 24 hours postinjection. All mi-
cro-PET images were reconstructed, and re-
gional tracer concentrations were quantified by
the use of the ASIPRO software package (Con-
corde Microsystems). Quantitative data, such as
accumulated activity of 64Cu in tumor, kidney,
and liver, were expressed as standardized uptake
values (SUVs), which is defined as the counts
per second per pixel in a region-of-interest
(ROI) encompassing the entire organ divided by
the total counts per second per pixel in the
mouse.
In Vivo Metabolism in A431 Tumor-Bearing
Nude Mice
Six (6) female nu/nu mice bearing 12-days A431
tumors were intravenously (i.v.) injected with
29.6–35.2 MBq (90 g) of 64Cu-DOTA-cetux-
imab. Blood, liver, and tumor were removed from
the mice at 4 and 20 hours postinjection; the liver
and tumor were rinsed with saline to remove as
much blood as possible. The blood, liver, and tu-
mor were homogenized in 0.1 M of ammonium
citrate buffer (pH 7.4), using a Tekmar tissue ho-
mogenizer, and sonicated for 1 minute. The sam-
ples were purified by centrifugation (23,500 g,
30 minutes), and the supernatants were saved for
size-exclusion HPLC analysis. Organ blanks,
where 64Cu-DOTA-cetuximab was added to tis-
sues ex vivo, were performed to determine
whether the extraction procedure affected the in-
tegrity of the radiolabeled antibody. For all me-
tabolism and organ blank samples, a 0.1-mL sam-
ple was first passed through a 0.45-micron
low-protein binding filter and then analyzed by
size-exclusion HPLC on a Superose 12 HR
10/300 gel filtration column eluted with 20 mM
of HEPES and 150 mM of NaCl (pH 7.4) buffer
at a flow rate of 0.5 mL/min. Fractions were col-
lected every minute and counted on a gamma
counter.
Additional blood and organ samples were an-
alyzed to determine the extraction efficiency. Af-
ter homogenization and centrifugation, the su-
pernatant was separated from the pellet and both
were counted in a gamma counter. The extrac-
tion efficiency was measured as the counts from
the supernatant divided by the total number of
counts for pellet and supernatant. Results are ex-
pressed as the percentages of the total dose.
Statistical Comparisons
Data are expressed as the mean  standard devi-
ation. The Student’s t-test (two-tailed) was per-
formed with Prism software to determine the sta-
tistical significance at the 95% confidence level,
with p 	 0.05 being considered significantly dif-
ferent.
RESULTS
Radiochemistry and In Vitro
Binding Affinity
It was determined that 5.5 DOTA chelators were
attached per molecule of cetuximab, resulting in
a specific activity of 64Cu-DOTA-cetuximab,
ranging from 0.4 to 1.1 MBq/g. The variance
in this specific activity was typically a result of
the specific activity of the 64Cu produced. The
radiolabeled conjugate was purified by using ei-
ther a Bio-spin 6 column filter or size-exclusion
HPLC and was confirmed to be greater than 95%
radiochemical purity by size-exclusion HPLC.
The binding affinity of 64Cu-DOTA-cetuximab
was determined by competitive displacement, us-
ing increasing concentrations of unlabeled ce-
tuximab in highly EGFR-expressing A431 and
low-expressing MDA-MB-435. The capacity of
64Cu-DOTA-cetuximab to inhibit EGFR, pre-
sented as IC50 to EGFR-expressing carcinoma
A431 cells, was determined to be 3.41 nM (95%
confidence intervals [CIs] of 2.83–4.11 nM);
however, there was no binding observed in
EGFR-negative MDA-MB-435 cells (Fig. 1A).
Nonspecific binding was tested in both cell lines
by the addition of 50 nM of unlabeled cetuximab
before the addition of 64Cu-DOTA-cetuximab.
Incubation of 64Cu-DOTA-cetuximab with A431
cells in the presence of 50 nM of unlabeled ce-
tuximab inhibited the binding by more than 90%,
suggesting 	10% nonspecific binding. In MDA-
MB-435 cells, less than 10% of 64Cu-DOTA-ce-
tuximab bound was observed at all concentrations
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of unlabeled cetuximab with no dose dependence,
demonstrating that the uptake of 64Cu-DOTA-ce-
tuximab was only nonspecific in this cell line.
The binding affinity of 64Cu-DOTA-cetuximab
was also investigated by determining the equi-
librium dissociation constant (KD) and the max-
imum specific binding (Bmax) of radiolabeled
conjugate to A431 cells in a saturation binding
assay. In a control experiment, a large excess of
unlabeled cetuximab was added to cells to satu-
rate the EGFR in order to demonstrate binding
specificity. A representative saturation binding
curve and Scatchard transformation of 64Cu-
DOTA-cetuximab to A431 cells are shown in
Figure 1B. The data show that 64Cu-DOTA-ce-
tuximab bound to a single class of binding sites
with a KD of 0.28 nM (95% CIs of 0.20–0.37 nM)
and a maximum binding capacity of 32,270
fmol/mg of protein (95% CIs of 29,746–34794
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Figure 1. (A) Competitive binding curves of cetuximab versus 64Cu-DOTA-cetuximab in A431 (epidermal growth-factor re-
ceptor [EGFR]-positive) and MDA-MB-435 (EGFR-negative) cells. IC50 of 64Cu-DOTA-cetuximab to A431 is 3.410 nM (95%
confidence intervals [CIs]: 2.832–4.107 nM). Each data point represents the mean  standard error of the mean (SEM) of trip-
licate measurements. (B) Saturation binding curves of 64Cu-DOTA-cetuximab to A431 cells. The KD of 64Cu-DOTA-cetuximab
was determined to be 0.28 nM (95% CIs: 0.20–0.37 nM) and the EGFR concentration in A431 cells (Bmax) was 32,270 fmol/mg
(95% CIs: 29,746–34,795 fmol/mg). Each data point represents the mean  SEM of triplicate measurements.
Table 1. Tissue Distribution of 64Cu-DOTA-Cetuximab in A431 and MDA-MB-435 Tumor Bearing Mice
A431 MDA-MB-435
Tissue 4 hours (n  8) 24 hours (n  17) 24 hours bl (n  9) 48 hours (n  13) 24 hours (n  5)
Blood 30.05  6.09 16.47  4.19 19.75  5.99 12.56  3.35 13.67  1.38
Lung 10.70  2.10 6.83  1.64 8.71  2.74 6.29  1.07 5.52  0.70
Kidney 6.04  0.94 4.25  0.92 5.60  1.62 5.05  0.60 3.61  0.39
Liver 17.60  6.11 12.70  4.88 11.07  2.89 15.34  2.94 9.55  3.29
Spleen 6.05  2.18 5.08  2.47 6.94  3.03 5.57  1.87 3.46  0.31
Heart 7.50  1.98 4.68  1.03 5.82  2.28 3.98  0.73 3.43  0.27
Stomach 1.97  0.39 1.68  0.65 2.37  0.80 2.12  0.34 1.26  0.46
Intestines 9.21  4.19 6.97  3.37 7.91  2.49 9.14  2.31 5.54  0.49
Muscle 2.04  1.08 2.22  0.48 2.86  0.86 1.87  0.51 1.97  0.16
Tumor 5.45  1.94 18.49  6.40 10.69  2.72 22.92  6.32 2.60  0.35
Tumorblood 0.19  0.026 1.15  0.091 0.56  0.033 1.84  0.080 0.32  0.26
Tumormuscle 2.96  0.41 8.61  0.84 3.81  0.18 12.4  0.52 2.32  2.04
Data are presented as the percent injected dose per g  standard deviation.
in agreement with the literature data for KD of
unlabeled cetuximab and binding sites of A431
cells, suggesting that the conjugation procedure
of DOTA to cetuximab did not affect the bind-
ing affinity of the antibody to A431 cells.7,20
In Vivo Biodistribution and Micro-PET
Imaging Studies
The biodistribution of 64Cu-DOTA-cetuximab
was performed in A431 and MDA-MB-435 tu-
mor-bearing mice, and the tissue uptake is shown
in Table 1 and Figure 2. The uptake of 64Cu-
DOTA-cetuximab in A431 tumors increased
steadily from 4 to 48 hours after the adminis-
tration of 64Cu-DOTA-cetuximab (4 hours:
5.45%  1.94% ID/g; 48 hours: 22.92% 
6.32% ID/g). The tumor uptake at 24 and 48
hours postinjection was significantly higher (p 	
0.03) than the uptake at both time points in all
other tissues, except for the blood at 24 hours.
There was a slow blood clearance of 64Cu-
DOTA-cetuximab, with 30.05%  6.09% ID/g at
4 hours to 12.56%  3.35% ID/g remaining at 48
hours, which is a common feature of intact mAbs.
EGFR-mediated uptake of 64Cu-DOTA-cetux-
imab in A431 tumors was demonstrated by the
injection of an excess of unlabeled cetuximab 20
hours prior to tracer injection and by comparison
with low-EGFR-expressing MDA-MB-435 tu-
mor xenografts. There was a significant differ-
ence in the EGFR-positive tumor uptake of 64Cu-
DOTA-cetuximab, compared to that of the
blocked uptake at 24 hours (18.49%  6.40% vs.
10.69%  2.72% ID/g; p 	 0.002). The negative
control tumor, MDA-MB-435, showed a 64Cu-
DOTA-cetuximab uptake of 2.6%  0.35% ID/g
at 24 hours, and this uptake value was signifi-
cantly lower than the uptake value at the same
time points for the A431 tumors (p 	 0.03). All
other tissues showed a similar uptake of 64Cu-
DOTA-cetuximab in A431 tumors with or with-
out the administration of cetuximab, and MDA-
MB-435 tumors at 24 hours postinjection.
The tumor:blood and tumor:muscle ratios in-
creased from 4 to 48 hours postinjection. At 4
hours, the tumor:blood ratio was 0.19  0.03,
and this increased to 1.84  0.08 at 48 hours.
Even though the tumor uptake at 24 and 48 hours
was not significantly different (p  0.07), the tu-
mor:blood ratio at 48 hours (1.84  0.08) was
higher than at 24 hours (1.15  0.09) (p 	
0.001). Tumor:muscle ratio increased from
2.96  0.40 at 4 hours to 12.4  0.50 at 48 hours
postinjection. The tumor:liver and tumor:kidney
ratios leveled out at 24 hours postinjection
(1.65  0.21 and 4.41  0.35, respectively).
Kidney uptake in A431 tumor-bearing mice
remained stable from 4 to 48 hours postinjec-
tion (6.04%  0.94% ID/g and 5.05%  0.60%
ID/g). In addition, the radioactivity in the liver
remained fairly constant, from 17.60%  6.11%
ID/g at 4 hours to 15.34%  2.94% ID/g at 48
hours. The excretion data in A431 tumor-bearing
mice demonstrated that only 0.97%  0.52% ID
of 64Cu was excreted from the urine by 4 hours
postinjection. By 24 hours postinjection, 18%
ID of 64Cu-DOTA-cetuximab activity was found
in the urine and feces and 34% ID of 64Cu-
DOTA-cetuximab activity in urine and feces at
48 hours postinjection (Table 2).
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Figure 2. Biodistribution of 64Cu-DOTA-cetuximab in
epidermal growth-factor receptor (EGFR)-positive A431
and EGFR-negative MDA-MB-435 tumor-bearing nude
mice. Data are presented as percent injected dose per
gram  standard deviation, n  5 for each time point. Bl,
blood; lg, lung; kd, kidney; lv, liver; sp, spleen; ht, heart;
st, stomach; Int, intestines; mu, muscle; tu, tumor. (A) Tis-
sue uptake of 64Cu-DOTA-cetuximab in A431 tumor
xenografts at 4 (n  8), 24 (n  17), and 48 hours (n  13)
postinjection. (B) Comparison of tissue uptake in A431
(control [n  17] and block [n  9] or MDA-MB-435 tu-
mor xenografts (n  5) at 24 hours postinjection. The group
of 9 A431 tumor-bearing mice received 1 mg of unlabeled
cetuximab per animal 20 hours prior to the administration
of the radioactive dose.
A
B
Micro-PET imaging was performed at 19 or 20
hours and 46 or 48 hours after the injection of
64Cu-DOTA-cetuximab in A431 and MDA-MB-
435 tumor-bearing mice and in mice contralater-
ally bearing both A431 and MDA-MB-435 tu-
mors. Tumor xenografts were clearly visible on
the micro-PET images of all A431 tumor-bear-
ing mice, which are shown in Figure 3. Also, as
in the biodistribution studies, a significant re-
duction of tumor uptake was observed in A431
mice receiving a blocking dose of unlabeled ce-
tuximab (1 mg, 20 hours in advance) (Fig. 3A).
There was also a significantly lower uptake in
MDA-MB-435 tumors, compared to A431 tu-
mors (Fig. 3B). Coregistered micro-PET/com-
puted tomography (CT) images were obtained at
24 hours postinjection for 64Cu-DOTA-cetux-
imab in mice bearing both A431 and MDA-MB-
435 tumors (Fig. 3). Consistent with the biodis-
tribution data, there was a higher uptake in the
A431 tumor than in the MDA-MB-435 tumor.
The accumulation of radioactivity in livers was
also visualized.
SUVs were also determined for tumors, livers,
and kidneys (Fig. 4). Tumor uptake of 64Cu-
DOTA-cetuximab in A431 mice at all time points
examined was greater than that in A431 mice ad-
ministrated unlabeled cetuximab. A good agree-
ment between the SUV analysis and the biodis-
tribution analysis for the tumor uptake (Fig. 4A)
was observed. The tumor uptake cleared slowly
and represented nearly the same radioactivity by
46 hours postinjection. In addition, nonspecific
liver uptake was observed in A431 tumor-bear-
ing mice (Fig. 4B). Comparison of the uptake in
tumor, liver, and kidneys by SUV between A431
tumor-bearing mice and MDA-MB-435 tumor-
bearing mice is shown in Figure 4C. The data
showed that there was a significantly greater up-
take of 64Cu-DOTA-cetuximab in A431 tumor
than in MDA-MB-435 tumor at 24 hours (p 	
0.05), and that the uptake in the liver or kidneys
was significantly lower than the uptake in A431
tumors (p 	 0.02).
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Table 2. Excretion of 64Cu-DOTA-Cetuximab in A431
Tumor-Bearing Mice
64Cu-DOTA-cetuximab
4 hours 24 hours 48 hours
Urine 0.97  0.52 1.06  0.65 1.87  0.77
Feces 0.47  0.14 15.48  2.18 13.81  1.83
All data are reported as the percent injected dose  
standard deviation.
Figure 3. (A) Projection microPET images of A431 tu-
mor-bearing nude mice after 20 and 46 hours postadminis-
tration of 64Cu-DOTA-cetuximab, with and without an in-
jected blocking dose 20 hours prior to the imaging dose (5.6
MBq, 6 g, left; 5.6 MBq, 1 mg of cetuximab, right). Ar-
row points to tumor. (B) Coronal micro-PET images of
64Cu-DOTA-cetuximab in A431 (epidermal growth-factor
receptor [EGFR]-positive) and MDA-MB-435 (EGFR-neg-
ative) tumor-bearing mice after 19 and 48 hours postad-
ministration of 64Cu-DOTA-cetuximab. Arrow points to tu-
mor. (C) Micro-PET/computed tomography coregistration
images of 64Cu-DOTA-cetuximab in a mouse bearing both





In Vivo Metabolism in A431 Tumor-Bearing
Nude Mice
By size-exclusion chromatography, 64Cu-DOTA-
cetuximab elutes at approximately 23 minutes,
corresponding to a 150-kDa protein (Fig. 5).
Liver, tumor, and blood sample homogenates
from A431 tumor-bearing mice were obtained at
4 and 20 hours postinjection of 64Cu-DOTA-
cetuximab and were analyzed by size-exclusion
chromatography to determine the extent of 64Cu
transchelation to other proteins and catabolites.
Representative size-exclusion chromatograms of
liver extracts obtained from rats sacrificed at 4
hours postinjection revealed that 64Cu-DOTA-
cetuximab undergoes a transchelation of 64Cu- 
to 64Cu-labeled proteins eluting at 29 and 33 
minutes, corresponding to 31 and 11 kDa
proteins, respectively. Small-molecular-weight
catabolites were also present, eluting at 36 min-
utes, corresponding to a molecular weight 	5
kDa. The liver extracts at 20 hours postinjection
revealed increased transchelation to the same pro-
tein masses.
Analysis of tumor extracts at 4 and 20 hours
postinjection showed a greater degree of tran-
schelation of 64Cu and/or catabolism, with ra-
dioactivity peaks corresponding to molecular
weight of 11 and less than 5 kDa. In addition,
a 64Cu-labeled species eluted at 16 minutes, cor-
responding to a very large molecular weight
(
1000 kDa), possibly indicating aggregated
protein or mAbs.
The percentage of authentic intact (%AI) 64Cu-
DOTA-cetuximab antibody (see Table 3) was
calculated for the blood, liver, and tumor ho-
mogenates at all time points. This calculation ac-
counts for 64Cu incorporation into other proteins,
as determined by the integration of peaks from
size-exclusion HPLC chromatograms and also
corrects for protein-extraction efficiency.21
Organ blank experiments were carried out to
ensure that the species observed after an i.v. in-
jection of the radiolabeled complexes were, in-
deed, the result of in vivo processes versus the







































































































Figure 4. Standard uptake values (SUV) obtained from
microPET images of 64Cu-DOTA-cetuximab in tumor-bear-
ing mice. (A) A431 tumor uptake of 64Cu-DOTA-cetuximab
with and without an injection of unlabeled cetuximab at var-
ious times of postinjection. (B) Liver uptake of 64Cu-DOTA-
cetuximab in A431 tumor-bearing mice with and without an
injection of unlabeled cetuximab at various times of postin-
jection. (C) Organ uptake of 64Cu-DOTA-cetuximab in mice
bearing both A431 and MDA-MB-435 tumors at 24 hours
postinjection.
Table 3. Amount of Authentic Intact (AI) 64Cu-DOTA-
Cetuximab in A431 Tumor-Bearing Mice
64Cu-DOTA-cetuximab
0 hours 4 hours 24 hours
Blood 96.70 96.07  2.910 96.15  1.94
Liver 95.45 33.98  12.95 32.75  4.95
Tumor 86.10 15.65  6.700 9.09  4.69
Values at 4 h and 24 h are reported as %AI  standard
deviation. (n  4), except for 4 hours blood, which is 



































































































































































Figure 5. Size-exclusion high-performance liquid chromatography analyses of blood, liver, and tumor samples at 4 and 24 hours
after an injection of 64Cu-DOTA-cetuximab in A431 tumor-bearing mice.
released upon lysing the cells during homoge-
nization and/or sonication. The 64Cu-DOTA-ce-
tuximab injectate was added ex vivo to liver and
blood samples from noninjected mice, and the
metabolism procedures were performed. These
control experiments indicated that the observed
incorporation of radiometal into intracellular pro-
teins was most likely owing to metabolic pro-
cesses in vivo and was not merely the result of
the techniques used to extract the metabolites
from the organs, except in the case of the tumor
blank samples.
DISCUSSION
Cetuximab, an anti-EGFR mAb, has shown con-
siderable activity in the treatment of metastatic col-
orectal cancer that is resistant to chemotherapy and
also is under ongoing investigational studies for
the treatment of non-small-cell lung cancer and
pancreatic cancer. However, the lack of a predic-
tive marker to predict responders to EGFR-tar-
geted mAb therapy limits the use of this agent to
patients with detectable EGFR expression.
There have been several recent reports in the
literature on whether the response of cancer to
cetuximab is correlated to the EGFR mRNA copy
number or EGFR protein levels. No correlation
has been found between the antitumor activity of
cetuximab and the levels of EGFR expression in
colorectal, lung, or pancreatic cancer.22–24 Mo-
roni et al. demonstrated a correlation in response
to cetuximab in patients with metastatic colorec-
tal cancer and EGFR copy number.25 Vallbohmer
et al. did not find a significant correlation be-
tween intratumoral EGFR gene expression and
response, possibly because of a small sample size
and low response rate.26 However, they observed
that patients with a higher gene expression of
EGFR had a shorter overall survival. It has also
been reported that even patients with no de-
tectable EGFR by immunohistochemistry tech-
niques have the potential to respond to cetux-
imab.27 These conflicting reports reflect that,
possibly, a more quantitative measure of EGFR
is needed to assess EGFR status in patients in or-
der to accurately determine whether there is any
correlation between EGFR gene expression
and/or EGFR protein levels and response to ce-
tuximab. In addition, the use of a PET marker of
cetuximab might assist in the dosing of cetux-
imab to assure that patients are receiving high
enough doses to be effective.
Although there is evidence that the expression
of EGFR does not necessarily correlate with the
therapeutic efficacy of cetuximab therapy, hav-
ing an imaging biomarker for EGFR expression
may still be important. Imaging EGFR expres-
sion has been explored with the murine antibody,
225, labeled with 111In and SPECT imaging,28
whereas the chimeric antibody cetuximab has
been labeled with 111In11,29,30 and 99mTc31,32 for
SPECT imaging. A recent report compared the
uptake of the positron-emitting radionuclide,
89Zr, radiolabeled to cetuximab with that of the
177Lu- and 88Y-labeled antibody.10,11,32,33 In this
study, we set out to determine if PET/CT imag-
ing with 64Cu-DOTA-cetuximab may be a more
sensitive and accurate measure of EGFR, com-
pared to traditional methods.
We first determined the binding affinity of
64Cu-DOTA-cetuximab to EGFR receptors in a
high-expressing tumor-cell line, A431. High
binding affinity of 64Cu-DOTA-cetuximab for
EGFR in A431 tumor membranes (KD  0.28
nM) was determined, and Scatchard analysis con-
firmed a high EGFR concentration in the A431
tumors (32,270 fmol/mg protein). These data
demonstrate that conjugating 64Cu-DOTA to ce-
tuximab does not adversely affect the binding of
cetuximab to EGFR. To the best of our knowl-
edge, these data represent the first quantitative
binding affinity data for a radiolabeled cetuximab
antibody with an EGFR-positive cell line. Wen
et al. reported that a DTPA-PEG-cetuximab con-
jugate retained 66% of the binding affinity of un-
conjugated cetuximab but did not report binding
constants or IC50 values.11
The tumor uptake of 64Cu-DOTA-cetuximab
increased between 4 and 24 hours and then re-
mained stable out to 48 hours; however, the con-
centration of 64Cu-DOTA-cetuximab in the blood
decreased, thereby increasing the tumor to blood
ratio at 48 hours. Blocking of 64Cu-DOTA-ce-
tuximab uptake with unlabeled cetuximab was
observed at both 24 and 48 hours, as well as de-
creased tumor uptake in a low-EGFR-express-
ing tumor model (MDA-MB-435). These data
demonstrate the specificity of 64Cu-DOTA-ce-
tuximab for the high-EGFR-expressing A431
tumor. Perk et al. reported the biodistribution 
of positron-emitting 89Zr-deferrioxamine-cetux-
imab, and the uptake in the tumor, blood, and
muscle are comparable to 64Cu-DOTA-cetux-
imab.33 The liver uptake of 89Zr-labeled cetux-
imab at 24 hours was somewhat lower (10%
ID/g) than was observed for the 64Cu-labeled
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conjugate (17.6%  0.60% ID/g), although the
89Zr uptake in the liver increased over time from
10% to 20% ID/g at 144 hours. Although
both 89Zr and 64Cu have been shown to give high-
quality PET images in clinical studies when ra-
diolabeled to mAbs,34,35 a disadvantage of 64Cu
is that the shorter half-life limits the imaging
times to 48 hours, or possibly 72 hours postin-
jection, whereas the 89Zr can be followed out to
144 hours. Comparison of 64Cu-DOTA-cetux-
imab with 111In-DTPA-PEG-cetuximab at 48
hours postinjection shows higher % ID/g blood
uptake (12.56% vs. 1.4%) with improved tumor
uptake (22% vs. 8.7%) and a markedly lower
liver uptake (14.3% vs. 25.5%).
Cai et al. reported the biodistribution of 64Cu-
DOTA-cetuximab in seven different EGFR-ex-
pressing tumor-bearing mouse models.13 The
highest tumor uptake was reported for U87MG,
which at 48 hours, showed approximately 12%
ID/g. In this study, we report 23% ID/g for A431
tumors, which was not described in the Cai et al.
study. Although the tumor uptake in our studies
was higher, the tumor:blood and tumor:muscle
ratios were comparable between A431 and
U87MG tumor-bearing mice.
It has been established that DOTA is not the
ideal chelator for 64Cu, as 64Cu-DOTA is not
highly stable in vivo and 64Cu dissociates and
binds to proteins in the blood and liver.36 Cross-
bridged macrocycles show much greater stabil-
ity with 64Cu; unfortunately, the enhanced ki-
netic and in vivo stability for biomolecule con-
jugates, such as CB-TE2A-conjugated Tyr3-oc-
treotate, results in the need for harsher labeling
conditions (95°C for 60 minutes),37 which are in-
compatible for protein labeling. Surprisingly, a
relatively high tumor uptake of 64Cu-DOTA-ce-
tuximab was observed at 48 hours postinjection
(22.92%  6.32% ID/g), whereas the liver and
blood uptake were significantly less (15.34% 
2.94% and 12.56%  3.35% ID/g, respectively;
p 	 0.01).33
Metabolism experiments were performed to de-
termine the extent of 64Cu transchelation to blood,
liver, and tumor proteins. These results showed
there was very little metabolism of 64Cu-DOTA-
cetuximab in the blood out to 24 hours postinjec-
tion (
95% AI at all time points), confirming that
the slow blood clearance was primarily owing to
slow clearance of the intact antibody. There was
relatively rapid metabolism in the liver (30% AI
at 4 hours); however, there was little further me-
tabolism between 4 and 24 hours postinjection.
Metabolism in the tumor was rapid, although the
tumor uptake continued to increase out to 48 hours
postinjection, suggesting that the metabolites do
not rapidly clear from the tumor.
Liver metabolism studies demonstrated that the
64Cu was shown to transchelate to three proteins,
as shown by size-exclusion chromatography.
Some of the protein-bound 64Cu in the liver at 4
and 20 hours postinjection eluted in a peak cor-
responding to a molecular weight of 31 kDa, con-
sistent with previous results showing SOD as a
primary radiolabeled protein in rat liver.36,38 An-
other radiolabeled protein, with an apparent mo-
lecular weight of 11 kDa, was also observed in
the size-exclusion chromatograms for both liver
and tumor, consistent with the apparent molecu-
lar weight of metallothionein, a class of ubiqui-
tous, low-molecular-weight, cysteine-rich, metal-
binding proteins that function in the metabolism
of zinc and copper. Previous studies performed
in our lab have shown similar results, with sizes
ranging from 11 to 14 kDa being attributed to
metallothionein.36
The tumor extracts at 4 hours postinjection
showed significant transchelation to a protein of
size 11 kDa as well as degradation to low-mo-
lecular-weight metabolites (	5 kDa). At 20
hours postinjection, even greater amounts of 64Cu
were bound to 	5-kDa metabolites. Copper-64
activity was observed at a retention time corre-
sponding to a protein weight of greater than 1000
kDa, and this is believed to be owing to protein
aggregation or, possibly (although less likely),
the 64Cu-DOTA-cetuximab is bound to EGFR-
containing protein complexes.39 In addition, it is
important to note that 64Cu-labeled SOD was not
observed in either time point in the tumor. One
possible explanation could be that the amount of
metallothionein present in the tumor is much
greater than what is found in other tissues, such
as the liver. Murphy et al. showed that hypoxic
conditions in human A431 tumors caused signif-
icant increase in the levels of metallothionein IIA
mRNA, which were also confirmed by Western
blotting.40 If there are high levels of metalloth-
ionein in these tumors, then the 64Cu may pref-
erentially transchelate to this over the potentially
lower levels of SOD.
CONCLUSIONS
In summary, 64Cu-DOTA-cetuximab was evalu-
ated as a PET-imaging agent for EGFR-positive
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tumors. High binding affinity of 64Cu-DOTA-ce-
tuximab for EGFR (0.28 nM) was demonstrated
in A431 cell membranes, and specific uptake of
the tracer was demonstrated in A431 tumor-bear-
ing mice. The uptake of 64Cu-DOTA-cetuximab
increased over time, whereas the tracer cleared
from the blood. The tumor was clearly visualized
by micro-PET in A431 tumor-bearing mice. 64Cu-
DOTA-cetuximab is a potential tracer for imag-
ing EGFR-positive tumors in humans. Although
it is still not clear whether 64Cu-DOTA-cetuximab
may be an accurate predictor of response to ce-
tuximab therapy, this agent will noninvasively
demonstrate the presence of EGFR as one of the
(potentially) multiple receptor types in the tumor
and may also help with dosing in patients to as-
sure that the EGFR receptors are saturated.
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